Cellbox Solutions, a Cologne company that makes portable incubators for transporting living cells and tissue, has closed its Series A round at €5m (about $5.6m). It announced the final close on 20 October 2026.
The round was built in two steps. About €3.5m came in a first close in March 2026 led by the crowd-investing platform Companisto. The final close added about €1.5m from members of Baltic Business Angels Invest, a Canadian family office and an unnamed investor with pharmaceutical logistics experience, the company said.
Existing investors NRW.BANK, the development bank of North Rhine-Westphalia, and Fraunhofer Venture also took part. No valuation was disclosed.
What Cellbox Solutions does
Cell and gene therapies, along with much biomedical research, depend on moving living biological material between labs, clinics and manufacturers. Cellbox makes mobile incubators that keep that material in controlled conditions while it travels. Both of its products are portable CO2 incubators that hold set temperature and CO2 levels, which users can adjust, during transport by road and by air. They are meant for living cells, organoids, tissues and other material that cannot be frozen, and Startbase contrasted this warm-chain approach with the traditional cold chain.
The company sells two products, the Cellbox Go and the Cellbox Shipper, and says more than 400 of its devices are on the market. It has Drug Master Files in place, regulatory filings that help pharmaceutical customers use its devices in regulated work. Startbase noted that the Drug Master Files should not be read as blanket approval for all medical uses.
Cellbox was founded in 2017. Its founder and chief executive is Kathrin Adlkofer, and Bernd Muehlenweg is chief business officer and chief financial officer. The company is based in Cologne and Hamburg, and its systems are used internationally in research, clinical studies and cell therapy.
What the money is for
Cellbox said it will use the funding to offer warm-chain logistics as a service, build recurring revenue from renting and monitoring its devices, and expand in Europe, Asia and North America. It plans partnerships with logistics providers so that its devices fit into existing transport networks, and services such as monitoring, fleet management and shipment coordination. Startbase reported that no specific partners or new locations were announced with the round.
In the announcement Adlkofer said the company had spent recent years building a solid base for the controlled transport of living biological materials. Muehlenweg said the focus now is on turning the strengths of the Cellbox platform into sustainable growth. "Completion of the Series A gives us additional resources to scale the commercial model behind our technology," Muehlenweg said, according to Startuprise. Startbase reported that Adlkofer sees the round as the basis for turning the platform into a broader logistics offering and expanding commercial operations faster.
The company has not disclosed its revenue or headcount.
The funding so far
Startbase and Startuprise both reported the final close. The investor list mixes public-sector backers, NRW.BANK and Fraunhofer Venture, with private angels, a family office and investors who came in through Companisto.
Cellbox did not give a figure for its total funding to date. Startbase reported that the valuation and the split of equity among investors were not disclosed.
Company website: cellbox-solutions.com